Antiplatelet versus anticoagulant therapy in patients with giant cell arteritis: Which is best? Commentary

Nature Clinical Practice Rheumatology

Volumn 3, Issue 3, 2007, Pages 136-137

  Stone, John H ^a  

^a UpToDate   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; GLUCOCORTICOID; PREDNISONE; WARFARIN;

BLEEDING; BLOOD VESSEL BIOPSY; BRAIN ISCHEMIA; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; GIANT CELL ARTERITIS; HEADACHE; HUMAN; INTRACARDIAC THROMBOSIS; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; STROKE; VISUAL IMPAIRMENT;

EID: 33947205241     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0431     Document Type: Short Survey

References (2)

1. Nesher G et al. (2004) Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50: 1332-1337
2. Stafford RS et al. (2005) Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med 2: E353